

SPECTRUM PHARMACEUTICALS INC

Form 8-K

March 27, 2008

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
March 24, 2008
Date of Report (Date of earliest event reported)**

**SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)**

**Delaware
(State or other Jurisdiction
of Incorporation)**

**000-28782
(Commission File Number)**

**93-0979187
(IRS Employer
Identification Number)**

**157 Technology Drive
Irvine, California
(Address of principal executive offices)**

**92618
(Zip Code)**

**(949) 788-6700
(Registrant's telephone number, including area code)**

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

SIGNATURES

Table of Contents

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 24, 2008, the Compensation Committee of the Board of Directors of Spectrum Pharmaceuticals, Inc. (the Company) approved fiscal 2007 bonus payments for the Company's named executive officers, as set forth below in the following table:

Name	Fiscal 2007 Bonus
Rajesh Shrotriya, Chairman, Chief Executive Officer and President	\$ 225,000
Luigi Lenaz, Chief Scientific Officer	\$ 60,000
Shyam Kumaria, Vice President, Finance	\$ 35,000

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 27, 2008

SPECTRUM PHARMACEUTICALS, INC.

By: /s/ Shyam Kumaria

Name: Shyam Kumaria

Title: V.P., Finance